Tillotts Pharma AG Overview
Pro stress-test →Tillotts Pharma is a leading international specialty pharmaceutical company with over 400 employees in Switzerland and abroad. The company is dedicated to the development, in and out-licensing and commercialization of innovative pharmaceutical products, medical devices and diagnostics, all in the field of gastroenterology. Tillotts has been part of the Japanese Zeria Group since 2009.
Strategic Profile
Pro stress-test →Tillotts markets its own products such as Asacol™ and Entocort™ as well as in-licensed products in around 50 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world. As a Zeria subsidiary, Tillotts leverages its parent company's resources and global reach to expand its specialty gastrointestinal pharmaceutical portfolio across multiple markets. The company focuses on therapeutic areas including inflammatory bowel disease, Clostridioides difficile infection, and other gastrointestinal conditions.
Competitive Landscape
Pro stress-test →Tillotts competes in the specialty gastroenterology pharmaceutical market against established players in inflammatory bowel disease and infectious gastrointestinal disease treatment. Key competitors include other specialty pharma companies focused on GI therapeutics. SLA Pharma is noted as one of Tillotts Pharma's competitors. The competitive landscape is characterized by both branded in-licensed products and proprietary formulations targeting similar therapeutic indications.
Industry Context
Tillotts Pharma AG operates in Specialty gastroenterology pharmaceuticals.
Key facts
Founded: 1950 · Headquarters: Rheinfelden, Switzerland · Employees: over 400